1 |
Yang LQ, Fang DC, Wang QR, Yang SM. 2004. Effect of NF-kB, survivin, Bcl-2 and caspase-3 on apoptosis of gastric cancer cells induced by tumor necrosis factor related apoptosis inducing ligand. World J Gastroenterol 10: 22-25.
DOI
|
2 |
Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS, Dixit VM. 1999. Yama/CPP32 , a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81: 801-809.
|
3 |
Griffith TS, Lynch DH. 1998. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 10: 559-563.
DOI
|
4 |
Falschlehner C, Emmerich CH, Gerlach B, Walczak H. 2007. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 39: 1462-1475.
DOI
ScienceOn
|
5 |
Siegelin MD, Siegelin Y, Habel A, Gaiser T. 2009. Genistein enhances proteasomal degradation of the short isoform of FLIP in malignant glioma cells and thereby augments TRAIL-mediated apoptosis. Neurosci Lett 453: 92-97.
DOI
|
6 |
Lian F, Bhuiyan M, Li YW, Wall N, Kraut M, Sarkar FH. 1998. Genistein-induced G2-M arrest, p21WAF1 upregulation, and apoptosis in a non-small-cell lung cancer cell line. Nutr Cancer 31: 184-191.
DOI
|
7 |
Choi YH, Lee WH, Park KY, Zhang L. 2000. p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn J Cancer Res 91: 164-173.
DOI
|
8 |
Choi YH, Zhang L, Lee WH, Park KY. 1998. Genistein-induced G2/M arrest is associated with the inhibition of cyclin B1 and the induction of p21 in human breast carcinoma cells. Int J Oncol 13: 391-396.
|
9 |
Harris P, Ralph P. 1985. Human leukemic models of myelomonocytic development: a review of the HL-60 and U937 cell lines. J Leukoc Biol 37: 407-422.
DOI
|
10 |
Raffoul JJ, Wang Y, Kucuk O, Forman JD, Sarkar FH, Hillman GG. 2006. Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer 6: 107.
DOI
|
11 |
Ouyang G, Yao L, Ruan K, Song G, Mao Y, Bao S. 2009. Genistein induces G2/M cell cycle arrest and apoptosis of human ovarian cancer cells via activation of DNA damage checkpoint pathways. Cell Biol Int 33: 1237-1244.
DOI
|
12 |
Zhao R, Xiang N, Domann FE, Zhong W. 2009. Effects of selenite and genistein on G2/M cell cycle arrest and apoptosis in human prostate cancer cells. Nutr Cancer 61: 397-407.
DOI
|
13 |
Zhang L, Fang B. 2005. Mechanisms of resistance to TRAIL induced apoptosis in cancer. Cancer Gene Ther 12: 228-237.
DOI
|
14 |
Pinski J, Wang Q, Quek ML, Cole A, Cooc J, Danenberg K, Danenberg PV. 2006. Genistein-induced neuroendocrine differentiation of prostate cancer cells. Prostate 66: 1136-1143.
DOI
|
15 |
Nozawa F, Itami A, SarucM, Kim M, Standop J, Picha KS, Cowan KH, Pour PM. 2004. The combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) and genistein is effective in inhibiting pancreatic cancer growth. Pancreas 29: 45-52.
DOI
|
16 |
Park SY, Seol DW. 2002. Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun 295: 515-518.
DOI
|
17 |
Jin CY, Park C, Cheong J, Choi BT, Lee TH, Lee JD, Lee WH, Kim GY, Ryu CH, Choi YH. 2007. Genistein sensitizes TRAIL-resistant human gastric adenocarcinoma AGS cells through activation of caspase-3. Cancer Lett 257: 56-64.
DOI
|
18 |
Szliszka E, Czuba ZP, Jernas K, Król W. 2008. Dietary flavonoids sensitize HeLa cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Int J Mol Sci 9: 56-64.
DOI
|
19 |
Bronikowska J, Szliszka E, Czuba ZP, Zwolinski D, Szmydki D, Krol W. 2010. The combination of TRAIL and isoflavones enhances apoptosis in cancer cells. Molecules 15: 2000-2015.
DOI
|
20 |
Jin CY, Park C, Kim GY, Lee SJ, Kim WJ, Choi YH. 2009. Genistein enhances TRAIL-induced apoptosis through inhibition of p38 MAPK signaling in human hepatocellular carcinoma Hep3B cells. Chem Biol Interact 180: 143-150.
DOI
|
21 |
Jin CY, Park C, Moon SK, Kim GY, Kwon TK, Lee SJ, Kim WJ, Choi YH. 2009. Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage. Anticancer Drugs 20: 713-722.
DOI
|
22 |
French LE, Tschopp J. 1999. The TRAIL to selective tumor death. Nat Med 5: 146-147.
DOI
|
23 |
Gilliland DG, Jordan CT, Felix CA. 2004. The molecular basis of leukemia. Hematology Am Soc Hematol Educ Program 2004: 80-97.
DOI
|
24 |
Abramson N, Melton B. 2000. Leukocytosis: basics of clinical assessment. Am Fam Physician 62: 2053-2060.
|
25 |
Wiernik PH. 1988. Leukemias and myeloma. Cancer Chemother Biol Response Modif 10: 129-147.
|
26 |
Wang S, EI-Deiry SW. 2003. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22: 8628-8633.
DOI
|
27 |
Srivastava RK. 2001. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 3: 535-546.
DOI
|
28 |
Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. 1999. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 59: 2747-2753.
|
29 |
Aggarwal B, Shishodia S. 2006. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71: 1397-1421.
DOI
|
30 |
Sarkar FH, Adsule S, Padhye S, Kulkarni S, Li Y. 2006. The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Mini Rev Med Chem 6: 401-407.
DOI
|